Functional Assay
Influence of FLT3L treatment on lymphocyte subpopulations. Method: C57BL/6 mice were injected intraperitoneally with 10 ug daily or were left untreated. (A) Percentages of indicated splenic subpopulations in FLT3L KO, WT control or WT-treated mice. (B) Absolute cell numbers of indicated splenic subpopulations in FLT3L KO, WT control, or WT-treated mice.
Functional Assay
Influence of FLT3L treatment on lymphocyte subpopulations. Method: C57BL/6 mice were injected intraperitoneally with 10 ug daily or were left untreated. (A) Percentages of indicated splenic subpopulations in FLT3L KO, WT control or WT-treated mice. (B) Absolute cell numbers of indicated splenic subpopulations in FLT3L KO, WT control, or WT-treated mice.
Functional Assay
Influence of FLT3L treatment on lymphocyte subpopulations. Method: C57BL/6 mice were injected intraperitoneally with 10 ug daily or were left untreated. (A) Percentages of indicated splenic subpopulations in FLT3L KO, WT control or WT-treated mice. (B) Absolute cell numbers of indicated splenic subpopulations in FLT3L KO, WT control, or WT-treated mice.
Functional Assay
Influence of FLT3L treatment on lymphocyte subpopulations. Method: C57BL/6 mice were injected intraperitoneally with 10 ug daily or were left untreated. (A) Percentages of indicated splenic subpopulations in FLT3L KO, WT control or WT-treated mice. (B) Absolute cell numbers of indicated splenic subpopulations in FLT3L KO, WT control, or WT-treated mice.